Article
An orally bioavailable tyrosine kinase inhibitor demonstrated dramatic and rapid effects on advanced prostate cancer, according to researchers from the University of Michigan Comprehensive Cancer Center, Ann Arbor.
Disitamab vedotin plus toripalimab shows safety, efficacy in MIBC
Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
EV/pembrolizumab continues to show OS, PFS benefit vs chemotherapy in la/mUC
Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC
Avelumab prolongs OS, PFS in advanced urothelial carcinoma irrespective of diabetes status
Real-world outcomes with nadofaragene point to safety, efficacy of NMIBC treatment